[1] Li H, He Z, Gu Y et al. Prioritization of non-coding disease-causing variants and long non-coding RNAs in liver cancer. Oncol Lett, 2016, 12:3987-3994.
[2] Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 2016, 22:9279-9287.
[3] Stang A, Donati M, Weilert H, et al. Impact of systemic therapy and recurrence pattern on survival outcome after radiofrequency ablation for colorectal liver metastases. J Cancer, 2016, 7:1939-1949.
[4] Li X, Dai X, Shi L, et al. Phase II/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases. Cell Physiol Biochem, 2016, 40:137-145.
[5] Lin M, Tian MM, Zhang WP, et al. Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. Onco Targets Ther, 2016, 9:7029-7037.
[6] Takano M, Kokudo T, Miyazaki Y, et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol, 2016, 22:9445-9450.
[7] 李群, 陆达锴, 崔翔, 等. 非编码 RNA 在喉癌发生中的作用及其临床意义. 中国细胞生物学学报, 2013, 35: 1797-1805.
[8] Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov, 2011, 1: 391-407.
[9] 刘坤,伍强. 射频消融和肝动脉化疗栓塞联合治疗中晚期肝癌的临床疗效. 肝脏,2018, 23: 620-622.
[10] 刘敏,吴武平. 肝癌患者射频消融时间与体温的相关性. 肝脏,2018, 23: 618-620.
[11] Ishikawa T, Abe S, Watanabe T, et al. Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma. Mol Clin Oncol, 2016, 5:511-516.
[12] Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget, 2016, 7:241-254. |
